Stay updated with breaking news from Sandrad Angelo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adaptimmune Therapeutics plc , a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel....
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Quebec Silica Resources Corp. (CSE: QTZ) ("Quebec Silica," or the "Company") is pleased to announce that a phase of fieldwork has been
Responses observed across a broad range of antigen expression - Initial safety and durability are encouraging - PHILADELPHIA, PA., and OXFORDSHIRE, U.K., May 20, 2021 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today. Data will be presented in an oral presentation by Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center...